Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ONO-2745/CNS 7056 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Subjects with moderate chronic hepatic impairment | EXPERIMENTAL | Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight |
| Healthy subjects matched to moderate hepatic impaired subjects | EXPERIMENTAL | Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight |
| Subjects with mild chronic hepatic impairment | EXPERIMENTAL | Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight |
| Healthy subjects matched to mild hepatic impaired subjects | EXPERIMENTAL | Single IV bolus of NO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight |
| Subjects with severe chronic hepatic impairment | EXPERIMENTAL | Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight |
| Name | Type | Description |
|---|---|---|
| ONO-2745 /CNS 7056 | DRUG | - |
Inclusion Criteria: * Males or females between 18 and 65 years of age * Negative test for the selected drugs of abuse at screening Hepatic impaired subjects: * Stable hepatic function and medication regimen for at least 28 days prior to check-in * Degree of hepatic impairment will be determined b...
ONO-2745/CNS 7056 is an investigational small molecule being studied for use in hepatic impairment. It is being developed by BrainsWay Ltd. (BWAY). The drug is in Phase 1 clinical development and has not been approved by regulatory authorities.
The molecular target of ONO-2745/CNS 7056 has not been disclosed. It is a small molecule being investigated for hepatic impairment, but its specific mechanism of action is not publicly available from the clinical trial data.
ONO-2745/CNS 7056 is being developed by BrainsWay Ltd., a company traded under the ticker BWAY. The drug is currently in Phase 1 clinical development for hepatic impairment.
ONO-2745/CNS 7056 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. One Phase 1 trial has been completed.
ONO-2745/CNS 7056 has one completed clinical trial, NCT01790607, titled "An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment." The study enrolled 20 participants in the United States and included healthy volunteers.
Yes, ONO-2745/CNS 7056 is also known as CNS 7056. The drug is being developed by BrainsWay Ltd. and is currently in Phase 1 clinical trials for hepatic impairment.